Drug
Vir 2218
Vir 2218: highest development phase Phase 2, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| VIR-2218 NCT04412863 | Phase 2 | Chronic Hepatitis B |
Latest
No recent events.
Follow Vir 2218 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.